Imagion Biosystems is pleased to announce it has raised $6M via a placement, at 8.5c per share.
The placement, led by Evolution Capital Advisors, was cornerstoned by four Australian-based institutional investors, and was met with very high demand.
- $6M raised in a heavily oversubscribed placement at 8.5c per share – a 6% discount to the 30-day VWAP.
- Placement strongly supported by institutional investors.
- Additional capital supports IBX development of the MagSenseTM HER2 breast cancer test for a
larger pivotal study including investing in manufacturing scale up.
Read the full announcement at ASX.